Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
AMA J Ethics ; 25(5): E365-374, 2023 05 01.
Article in English | MEDLINE | ID: mdl-37132622

ABSTRACT

Milwaukee has become home to one of the largest US populations of Rohingya refugees, who face barriers to health care, including poor service integration impeded by the absence of a formal written language. Clinicians also face barriers to delivering adequate, culturally attuned health services, so suboptimal outcomes are common. This article describes a community-based intervention using an interprofessional, multi-organizational, and ethnographically focused approach to address Rohingya refugee health needs that incorporates Rohingya participants' making educational videos in their native language. Mutually beneficial outcomes are outlined for Rohingya, students, and clinicians.


Subject(s)
Refugees , Humans , Delivery of Health Care , Health Services , Language , Students
2.
Clin Sci (Lond) ; 135(11): 1333-1351, 2021 06 11.
Article in English | MEDLINE | ID: mdl-34076246

ABSTRACT

Recent advances in treatment have transformed the management of cancer. Despite these advances, cardiovascular disease remains a leading cause of death in cancer survivors. Cardio-oncology has recently evolved as a subspecialty to prevent, diagnose, and manage cardiovascular side effects of antineoplastic therapy. An emphasis on optimal management of comorbidities and close attention to drug interactions are important in cardio-oncologic care. With interdisciplinary collaboration among oncologists, cardiologists, and pharmacists, there is potential to prevent and reduce drug-related toxicities of treatments. The cytochrome P450 (CYP450) family of enzymes and the P-glycoprotein (P-g) transporter play a crucial role in drug metabolism and drug resistance. Here we discuss the role of CYP450 and P-g in drug interactions in the field of cardio-oncology, provide an overview of the cardiotoxicity of a spectrum of cancer agents, highlight the role of precision medicine, and encourage a multidisciplinary treatment approach for patients with cancer.


Subject(s)
Antineoplastic Agents/therapeutic use , Cardiotoxicity/drug therapy , Cardiovascular Diseases/drug therapy , Neoplasms/drug therapy , Precision Medicine , Aged , Female , Humans , Medical Oncology , Precision Medicine/methods
3.
J Am Med Inform Assoc ; 28(1): 113-118, 2021 01 15.
Article in English | MEDLINE | ID: mdl-33186450

ABSTRACT

OBJECTIVE: Wrong drug product errors occurring in community pharmacies often originate at the transcription stage. Electronic prescribing and automated product selection are strategies to reduce product selection errors. However, it is unclear how often automated product selection succeeds in outpatient pharmacy platforms. MATERIALS AND METHODS: The intake of over 800 e-prescriptions was observed at baseline and after intervention to assess the rate of automated product selection success. A dispensing accuracy audit was performed at baseline and postintervention to determine whether enhanced automated product selection would result in greater accuracy; data for both analyses were compared by 2x2 Chi square tests. In addition, an anonymous survey was sent to a convenience sample of 60 area community pharmacy managers. RESULTS: At baseline, 79.8% of 888 e-prescriptions achieved automated product selection. After the intervention period, 84.5% of 903 e-prescriptions achieved automated product selection (P = .008). Analysis of dispensing accuracy audits detected a slight but not statistically significant improvement in accuracy rate (99.3% versus 98.9%, P = .359). Fourteen surveys were returned, revealing that other community pharmacies experience similar automated product selection failure rates. DISCUSSION: Our results suggest that manual product selection by pharmacy personnel is required for a higher than anticipated proportion of e-prescriptions received and filled by community pharmacies, which may pose risks to both medication safety and efficiency. CONCLUSION: The question of how to increase automated product selection rates and enhance interoperability between prescriber and community pharmacy platforms warrants further investigation.


Subject(s)
Community Pharmacy Services , Electronic Prescribing , Medication Errors , Drug Prescriptions , Electronic Prescribing/statistics & numerical data , Health Information Interoperability , Humans , Medication Errors/prevention & control , Medication Errors/statistics & numerical data , Pharmacists , RxNorm , Surveys and Questionnaires
4.
J Interprof Care ; 34(1): 27-35, 2020.
Article in English | MEDLINE | ID: mdl-31381470

ABSTRACT

The objective of this manuscript is to describe the results of a pharmacist-driven, Type 2 diabetes targeted, collaborative practice within an urban, underserved federally qualified health center. Pharmacists within a primary care team managed patients with chronic illnesses utilizing a collaborative practice agreement. Pharmacists, pharmacy residents, and supervised students provided care for patients with Type 2 diabetes. The first visit incorporated past medical history, medication reconciliation, determination of adherence and patient knowledge of diabetes pathophysiology, care plan, including diet and exercise, medications, and possible complications. Pharmacists had the authority to optimize medications and order laboratory tests and referrals. Diabetes, hypertension, and medication use outcomes data were collected and analyzed to assess the impact of clinical pharmacy services. Patient and provider satisfaction were assessed via surveys and focus group interviews. Ninety-nine patients were included in the evaluation. The mean A1c level was 9.8% at baseline and 8.4% at follow-up (p< .05). There were significant improvements in patient attainment of A1c <9%, ACE Inhibitor/angiotensin receptor blocker and statin use, and tobacco cessation at follow-up (p< .05). Eleven providers who responded to the satisfaction survey answered 73% of the questions with strongly agree. The seven patients who participated in the satisfaction survey, and focus group were satisfied with the care they received from the pharmacists. The focus group highlighted similar personal goals, barriers, and interests in nutrition education. Working as part of a collaborative care team, pharmacists were able to have a significant impact on improving the health outcomes of patients with Type 2 diabetes and patient and provider perceptions of the vital role of pharmacists.


Subject(s)
Diabetes Mellitus, Type 2/therapy , Disease Management , Interprofessional Relations , Pharmacists/organization & administration , Safety-net Providers/organization & administration , Adult , Aged , Aged, 80 and over , Animals , Cardiovascular Agents/administration & dosage , Female , Glycated Hemoglobin , Health Knowledge, Attitudes, Practice , Healthy Lifestyle , Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage , Male , Medically Underserved Area , Middle Aged , Patient Care Team/organization & administration , Pectinidae , Primary Health Care/organization & administration , Smoking Cessation/statistics & numerical data , Socioeconomic Factors , Urban Population , Vulnerable Populations
5.
Appl Environ Microbiol ; 82(1): 218-31, 2016 01 01.
Article in English | MEDLINE | ID: mdl-26497452

ABSTRACT

Approximately 30 years ago, it was discovered that free-living bacteria isolated from cold ocean depths could produce polyunsaturated fatty acids (PUFA) such as eicosapentaenoic acid (EPA) (20:5n-3) or docosahexaenoic acid (DHA) (22:6n-3), two PUFA essential for human health. Numerous laboratories have also discovered that EPA- and/or DHA-producing bacteria, many of them members of the Shewanella genus, could be isolated from the intestinal tracts of omega-3 fatty acid-rich marine fish. If bacteria contribute omega-3 fatty acids to the host fish in general or if they assist some bacterial species in adaptation to cold, then cold freshwater fish or habitats should also harbor these producers. Thus, we undertook a study to see if these niches also contained omega-3 fatty acid producers. We were successful in isolating and characterizing unique EPA-producing strains of Shewanella from three strictly freshwater native fish species, i.e., lake whitefish (Coregonus clupeaformis), lean lake trout (Salvelinus namaycush), and walleye (Sander vitreus), and from two other freshwater nonnative fish, i.e., coho salmon (Oncorhynchus kisutch) and seeforellen brown trout (Salmo trutta). We were also able to isolate four unique free-living strains of EPA-producing Shewanella from freshwater habitats. Phylogenetic and phenotypic analyses suggest that one producer is clearly a member of the Shewanella morhuae species and another is sister to members of the marine PUFA-producing Shewanella baltica species. However, the remaining isolates have more ambiguous relationships, sharing a common ancestor with non-PUFA-producing Shewanella putrefaciens isolates rather than marine S. baltica isolates despite having a phenotype more consistent with S. baltica strains.


Subject(s)
Fatty Acids, Omega-3/biosynthesis , Fishes/microbiology , Shewanella/isolation & purification , Shewanella/metabolism , Water Microbiology , Animals , DNA, Bacterial , Eicosapentaenoic Acid/biosynthesis , Fresh Water/microbiology , Gastrointestinal Tract/microbiology , Humans , Lakes/microbiology , Microbiota/physiology , Molecular Sequence Data , Phenotype , Phylogeny , RNA, Ribosomal, 16S , Shewanella/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...